These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 21120364)

  • 81. Treatment with benznidazole and pentoxifylline regulates microRNA transcriptomic profile in a murine model of Chagas chronic cardiomyopathy.
    Silva Grijó Farani P; Iandra da Silva Ferreira B; Begum K; Vilar-Pereira G; Pereira IR; Fernández-Figueroa EA; Cardenas-Ovando RA; Almeida IC; Roy S; Lannes-Vieira J; Moreira OC
    PLoS Negl Trop Dis; 2023 Mar; 17(3):e0011223. PubMed ID: 36972298
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Biological characteristics of the Trypanosoma cruzi Arequipa strain make it a good model for Chagas disease drug discovery.
    Martín-Escolano R; Rosales MJ; Marín C
    Acta Trop; 2022 Dec; 236():106679. PubMed ID: 36096184
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Trypanocidal activity of 4 isopropyl salicylaldehyde and 4-isopropyl salicylic acid on Trypanosoma cruzi.
    Nogueda-Torres B; Rodríguez-Paez L; Ramírez IB; Ramírez CW
    Rev Latinoam Microbiol; 2001; 43(1):1-6. PubMed ID: 17061565
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Benefits of Ascorbic Acid in Association with Low-Dose Benznidazole in Treatment of Chagas Disease.
    Providello MV; Carneiro ZA; Portapilla GB; do Vale GT; Camargo RS; Tirapelli CR; de Albuquerque S
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29987143
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Putative Role of the Aldo-Keto Reductase from Trypanosoma cruzi in Benznidazole Metabolism.
    Garavaglia PA; Laverrière M; Cannata JJ; García GA
    Antimicrob Agents Chemother; 2016 May; 60(5):2664-70. PubMed ID: 26856844
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Randomized trial of posaconazole and benznidazole for chronic Chagas' disease.
    Molina I; Gómez i Prat J; Salvador F; Treviño B; Sulleiro E; Serre N; Pou D; Roure S; Cabezos J; Valerio L; Blanco-Grau A; Sánchez-Montalvá A; Vidal X; Pahissa A
    N Engl J Med; 2014 May; 370(20):1899-908. PubMed ID: 24827034
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Trypanosoma cruzi genetic diversity: Something new for something known about Chagas disease manifestations, serodiagnosis and drug sensitivity.
    Zingales B
    Acta Trop; 2018 Aug; 184():38-52. PubMed ID: 28941731
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Effects of dehydroepiandrosterone-sulfate (DHEA-S) and benznidazole treatments during acute infection of two different Trypanosoma cruzi strains.
    Santos CD; Loria RM; Oliveira LG; Kuehn CC; Toldo MP; Albuquerque S; do Prado JC
    Immunobiology; 2010 Dec; 215(12):980-6. PubMed ID: 20163889
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Pentamidine antagonizes the benznidazole's effect in vitro, and lacks of synergy in vivo: Implications about the polyamine transport as an anti-Trypanosoma cruzi target.
    Seguel V; Castro L; Reigada C; Cortes L; Díaz MV; Miranda MR; Pereira CA; Lapier M; Campos-Estrada C; Morello A; Kemmerling U; Maya JD; López-Muñoz R
    Exp Parasitol; 2016 Dec; 171():23-32. PubMed ID: 27729250
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Activity profile of two 5-nitroindazole derivatives over the moderately drug-resistant
    Fonseca-Berzal C; da Silva CF; Batista DDGJ; de Oliveira GM; Cumella J; Batista MM; Peres RB; Silva da Gama Nefertiti A; Escario JA; Gómez-Barrio A; Arán VJ; Soeiro MNC
    Parasitology; 2020 Sep; 147(11):1216-1228. PubMed ID: 32530391
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Trypanosoma cruzi infection of human induced pluripotent stem cell-derived cardiomyocytes: an in vitro model for drug screening for Chagas disease.
    da Silva Lara L; Andrade-Lima L; Magalhães Calvet C; Borsoi J; Lopes Alberto Duque T; Henriques-Pons A; Souza Pereira MC; Veiga Pereira L
    Microbes Infect; 2018 May; 20(5):312-316. PubMed ID: 29577969
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Molecular characterization of Cyclophilin (TcCyP19) in Trypanosoma cruzi populations susceptible and resistant to benznidazole.
    Rêgo JV; Duarte AP; Liarte DB; de Carvalho Sousa F; Barreto HM; Bua J; Romanha AJ; Rádis-Baptista G; Murta SM
    Exp Parasitol; 2015 Jan; 148():73-80. PubMed ID: 25450774
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Elucidating the impact of low doses of nano-formulated benznidazole in acute experimental Chagas disease.
    Rial MS; Scalise ML; Arrúa EC; Esteva MI; Salomon CJ; Fichera LE
    PLoS Negl Trop Dis; 2017 Dec; 11(12):e0006119. PubMed ID: 29267280
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Technological innovation strategies for the specific treatment of Chagas disease based on Benznidazole.
    Ferraz LRM; Alves AÉG; Nascimento DDSDS; Amariz IAE; Ferreira AS; Costa SPM; Rolim LA; Lima ÁAN; Rolim Neto PJ
    Acta Trop; 2018 Sep; 185():127-132. PubMed ID: 29452113
    [TBL] [Abstract][Full Text] [Related]  

  • 95. In vitro investigation of the efficacy of novel diamidines against Trypanosoma cruzi.
    Timm BL; Da Silva PB; Batista MM; Farahat AA; Kumar A; Boykin DW; Soeiro MN
    Parasitology; 2014 Sep; 141(10):1272-6. PubMed ID: 24735493
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Antitrypanosomal Activity of Sterol 14α-Demethylase (CYP51) Inhibitors VNI and VFV in the Swiss Mouse Models of Chagas Disease Induced by the Trypanosoma cruzi Y Strain.
    Guedes-da-Silva FH; Batista DG; Da Silva CF; De Araújo JS; Pavão BP; Simões-Silva MR; Batista MM; Demarque KC; Moreira OC; Britto C; Lepesheva GI; Soeiro MN
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167559
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Nifurtimox response of
    Munoz-Calderon A; Díaz-Bello Z; Ramírez JL; Noya O; de Noya BA
    J Vector Borne Dis; 2019; 56(3):237-243. PubMed ID: 32655073
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Usefulness of the polymerase chain reaction for monitoring cure of mice infected with different Trypanosoma cruzi clonal genotypes following treatment with benznidazole.
    Miyamoto CT; Gomes ML; Marangon AV; de Araújo SM; Bahia MT; Martins-Filho OA; de Lana M; de Ornelas Toledo MJ
    Exp Parasitol; 2008 Sep; 120(1):45-9. PubMed ID: 18533149
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Drug transporter and oxidative stress gene expression in human macrophages infected with benznidazole-sensitive and naturally benznidazole-resistant Trypanosoma cruzi parasites treated with benznidazole.
    Téllez J; Romero I; Romanha AJ; Steindel M
    Parasit Vectors; 2019 May; 12(1):262. PubMed ID: 31126349
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Trypanosoma cruzi: biological characterization of a isolate from an endemic area and its susceptibility to conventional drugs.
    Grosso NL; Bua J; Perrone AE; Gonzalez MN; Bustos PL; Postan M; Fichera LE
    Exp Parasitol; 2010 Oct; 126(2):239-44. PubMed ID: 20493848
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.